{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023882","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.890052+00:00","generated_at":"2026-06-22T02:12:32.404674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M","bullets":["Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.","R&D expenses increased vs. Q3 2021 due to license fee, clinical activity, and personnel costs.","Enrollment ongoing in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; Phase 2 top-line data expected ~9 months after enrollment completion.","Awarded up to $17.8M NIAID contract to develop epetraborole for acute systemic melioidosis.","Phase 1 study in Japanese subjects supports 500mg once-daily dose regardless of ADH genotype."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023882","json":"https://secwatch.observer/filing/0000950170-22-023882.json","markdown":"https://secwatch.observer/filing/0000950170-22-023882.md","text":"https://secwatch.observer/filing/0000950170-22-023882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/0000950170-22-023882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/antx-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:12:32.404674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06adce0b2cc091eb01aa318cb53f730e907908ee","claim":"AN2 Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"AN2 Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/0000950170-22-023882-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}